BEAM

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,166

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.66 to $37.65, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,691

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,394

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-23-000973 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,068

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-23-000237 · doc4.xml · derivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,202

Underlying: Common Stock · 4,500 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this stock option vested 25% on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

F2 · balance_after: On April 2, 2021, the reporting person filed a Form 4 which inadvertently reported in column 9 that, following his exercise of an option, the number of derivative securities beneficially owned was 265,414 shares, when this number should have been reported as 253,414 shares. This Form 4 reflects the corrected number of derivative securities beneficially owned following the transactions reported since April 2, 2021, including the transaction reported herein.

SEC source: 0000899243-23-000237 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-038538 · doc4.xml · derivative · entry 7

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,326

Underlying: Common Stock · 8,652 shares

Expires 2029-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F7 · derivative.exercise_date: The option award vests upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.

SEC source: 0000899243-22-038538 · doc4.xml · derivative · entry 6

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,491

Underlying: Common Stock · 18,211 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F6 · derivative.exercise_date: 25% of the shares subject to the stock option vested on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.

SEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 5

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,462

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $44.06, inclusive.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.76 to $44.06, inclusive.

SEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 4

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,845

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $44.06, inclusive.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.76 to $43.75, inclusive.

SEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 3

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,778

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $44.06, inclusive.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $42.71, inclusive.

SEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 2

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,477

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-22-038538 · doc4.xml · nonDerivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,825

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

SEC source: 0000899243-22-039103 · doc4a.xml · derivative · entry 1

Ciaramella Giuseppe · CIK 0001786322 · President & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,106

Underlying: Common Stock · 18,211 shares

Expires 2028-05-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On December 14, 2022, the reporting person filed a Form 4 which inadvertently attributed a stock option exercise to the incorrect stock option award. The stock option that was the subject of the reported exercise is the stock option award originally reported on September 9, 2021. Accordingly, the first line of Table 2 of this Form 4 reflects this correction.

F2 · kind: The stock option exercise was effected pursuant to a Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: The option award vests upon the achievement of a closing price hurdle following Beam Therapeutics Inc.'s initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.

SEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 8

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 103,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.57 to $48.40, inclusive.

SEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 105,188

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.57 to $47.555, inclusive.

SEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 113,423

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $45.57 to $46.56, inclusive.

SEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 117,992

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $44.48 to $45.445, inclusive.

SEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,058,520

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.68 to $48.17, inclusive.

SEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,061,429

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $46.57 to $47.52, inclusive.

SEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,073,185

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $45.57 to $46.56, inclusive.

SEC source: 0000899243-22-034759 · doc4.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,080,953

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $44.48 to $45.445, inclusive.

SEC source: 0000315066-22-001715 · primary_doc.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 0

SEC source: 0000315066-22-001715 · primary_doc.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 551

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001715 · primary_doc.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 0

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000899243-22-030271 · doc4.xml · derivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,391

Underlying: Common Stock · 10,391 shares

Expires 2032-09-01

F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000899243-22-030277 · doc4.xml · derivative · entry 1

Burow Kristina · CIK 0001569248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,391

Underlying: Common Stock · 10,391 shares

Expires 2032-09-01

F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000899243-22-030278 · doc4.xml · derivative · entry 1

Ho Carole · CIK 0001724605 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,391

Underlying: Common Stock · 10,391 shares

Expires 2032-09-01

F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000899243-22-030272 · doc4.xml · derivative · entry 1

COOPER GRAHAM K · CIK 0001396943 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,391

Underlying: Common Stock · 10,391 shares

Expires 2032-09-01

F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000899243-22-030269 · doc4.xml · derivative · entry 1

Walsh Kathleen E · CIK 0001667866 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,391

Underlying: Common Stock · 10,391 shares

Expires 2032-09-01

F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000899243-22-030270 · doc4.xml · derivative · entry 1

Fishman Mark · CIK 0001786003 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,391

Underlying: Common Stock · 10,391 shares

Expires 2032-09-01

F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 9

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 0

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 8

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 0

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 7

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Disclosed balance after: 2,803,027

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 6

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 20,159

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 25,620

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 193,184

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 167

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 375,536

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000315066-22-001678 · primary_doc.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 2,135,511

F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 9

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 123,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.72 to $68.49, inclusive.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 8

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 125,247

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.50 to $66.61, inclusive.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 7

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 125,448

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.46 to $66.45, inclusive.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 6

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By John M. Evans, III 2018 Irrevocable Trust

Disclosed balance after: 136,047

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.38, inclusive.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 5

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,088,520

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 4

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,088,693

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $67.45 to $67.87, inclusive.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 3

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,091,541

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $66.44 to $67.37, inclusive.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 2

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,093,103

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $65.43 to $66.34, inclusive.

SEC source: 0000899243-22-027077 · doc4.xml · nonDerivative · entry 1

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,108,339

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $64.43 to $65.42, inclusive.

SEC source: 0000899243-22-016164 · doc4.xml · derivative · entry 14

Evans John M. · CIK 0001786304 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,141

Underlying: Common Stock · 47,204 shares

Expires 2028-07-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F13 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, October 1, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.